Related Experiment Videos

Grepafloxacin inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in human airway epithelial cells

S Hashimoto1, K Matsumoto, Y Gon

  • 1First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. shuh@med.nihon-u.ac.jp

Life Sciences
|February 12, 2000
PubMed

Insights

Grepafloxacin (GPFX) reduced interleukin-8 (IL-8) protein and mRNA in airway cells stimulated by tumor necrosis factor-alpha (TNF-alpha). This fluoroquinolone shows potential for managing chronic airway inflammatory diseases.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Respiratory Medicine

Background:

  • Interleukin-8 (IL-8) is a key cytokine in airway inflammation.
  • Tumor necrosis factor-alpha (TNF-alpha) stimulates IL-8 production in airway epithelial cells.
  • New antimicrobial agents are investigated for immunomodulatory effects in respiratory diseases.

Purpose of the Study:

  • To investigate the effect of grepafloxacin (GPFX) on IL-8 expression in human airway epithelial cells (AEC).
  • To determine if GPFX can modulate TNF-alpha-induced IL-8 production.

Main Methods:

  • Human airway epithelial cells (AEC) were stimulated with TNF-alpha.
  • Cells were treated with varying concentrations of grepafloxacin (GPFX) (2.5 - 25 micro g/ml).
  • IL-8 protein production and mRNA expression were measured.

Main Results:

  • GPFX significantly inhibited IL-8 protein production in a concentration-dependent manner.
  • GPFX also inhibited IL-8 mRNA expression in a concentration-dependent manner.
  • Complete inhibition of IL-8 expression was not observed at tested concentrations in serum and airway lining fluids.

Conclusions:

  • Grepafloxacin exhibits a concentration-dependent inhibitory effect on IL-8 production and expression in AEC.
  • GPFX may have a role in modulating airway inflammation.
  • Further research is warranted to explore GPFX's efficacy in chronic airway inflammatory diseases.

Related Concept Videos